drugset / Trial / NCT07314905
Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp)
Phase 3
Not yet recruiting
264 enrolled
Unity Health Toronto
Canadian Institutes of Health Research (CIHR) · collabHealth Canada · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
TreatResp is a double-blind, individually randomized, multi-centre adaptive platform trial. TreatResp aims to establish an adaptive platform trial aimed at evaluating the clinical- and cost-effectiveness, practical challenges, and outcomes of therapeutics for respiratory pathogens in non-hospitalized patients. Participants will be randomized to receive usual care (i.e., supportive care and symptom relief) or a study therapeutic, which will be determined by the TreatResp Therapeutics Committee. The primary outcomes being evaluated is time to recovery.
Timeline
- Start
- 2026-01-02
- Primary completion
- 2027-03-31
- Completion
- 2027-04-24